Overview

A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC)

Status:
Not yet recruiting

Trial end date:
2029-06-19

Target enrollment:

Participant gender:

Summary

To assess the efficacy and safety of osimertinib in participants with EGFRm positive stage II-IIIB NSCLC, following complete tumour resection with or without adjuvant chemotherapy.

Phase:

Phase 2

Details

Lead Sponsor:

AstraZeneca

Treatments:

Osimertinib